16
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Targeting psychologic stress signaling pathways in Alzheimer’s disease

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Alzheimer’s Disease (AD) is the most prevalent progressive neurodegenerative disease; to date, no AD therapy has proven effective in delaying or preventing the disease course. In the search for novel therapeutic targets in AD, it has been shown that increased chronic psychologic stress is associated with AD risk. Subsequently, biologic pathways underlying psychologic stress have been identified and shown to be able to exacerbate AD relevant pathologies. In this review, we summarize the literature relevant to the association between psychologic stress and AD, focusing on studies investigating the effects of stress paradigms on transgenic mouse models of Amyloid-β (Aβ) and tau pathologies. In recent years, a substantial amount of research has been done investigating a key stress-response mediator, corticotropin-releasing hormone (CRH), and its interactions with AD relevant processes. We highlight attempts to target the CRH signaling pathway as a therapeutic intervention in these transgenic mouse models and discuss how targeting this pathway is a promising avenue for further investigation.

          Related collections

          Most cited references67

          • Record: found
          • Abstract: found
          • Article: not found

          Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease.

          Various environmental and genetic factors influence the onset and progression of Alzheimer's disease (AD). Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, which controls circulating levels of glucocorticoid hormones, occurs early in AD, resulting in increased cortisol levels. Disturbances of the HPA axis have been associated with memory impairments and may contribute to the cognitive decline that occurs in AD, although it is unknown whether such effects involve modulation of the amyloid beta-peptide (Abeta) and tau. Using in vitro and in vivo experiments, we report that stress-level glucocorticoid administration increases Abeta formation by increasing steady-state levels of amyloid precursor protein (APP) and beta-APP cleaving enzyme. Additionally, glucocorticoids augment tau accumulation, indicating that this hormone also accelerates the development of neurofibrillary tangles. These findings suggest that high levels of glucocorticoids, found in AD, are not merely a consequence of the disease process but rather play a central role in the development and progression of AD.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse.

            Two G protein-coupled receptors have been identified that bind corticotropin-releasing factor (CRF) and urocortin (UCN) with high affinity. Hybridization histochemical methods were used to shed light on controversies concerning their localization in rat brain, and to provide normative distributional data in mouse, the standard model for genetic manipulation in mammals. The distribution of CRF-R1 mRNA in mouse was found to be fundamentally similar to that in rat, with expression predominating in the cerebral cortex, sensory relay nuclei, and in the cerebellum and its major afferents. Pronounced species differences in distribution were few, although more subtle variations in the relative strength of R1 expression were seen in several forebrain regions. CRF-R2 mRNA displayed comparable expression in rat and mouse brain, distinct from, and more restricted than that of CRF-R1. Major neuronal sites of CRF-R2 expression included aspects of the olfactory bulb, lateral septal nucleus, bed nucleus of the stria terminalis, ventromedial hypothalamic nucleus, medial and posterior cortical nuclei of the amygdala, ventral hippocampus, mesencephalic raphe nuclei, and novel localizations in the nucleus of the solitary tract and area postrema. Several sites of expression in the limbic forebrain were found to overlap partially with ones of androgen receptor expression. In pituitary, rat and mouse displayed CRF-R1 mRNA signal continuously over the intermediate lobe and over a subset of cells in the anterior lobe, whereas CRF-R2 transcripts were expressed mainly in the posterior lobe. The distinctive expression pattern of CRF-R2 mRNA identifies additional putative central sites of action for CRF and/or UCN. Constitutive expression of CRF-R2 mRNA in the nucleus of the solitary tract, and stress-inducible expression of CRF-R1 transcripts in the paraventricular nucleus may provide a basis for understanding documented effects of CRF-related peptides at a loci shown previously to lack a capacity for CRF-R expression or CRF binding. Other such "mismatches" remain to be reconciled. Copyright 2000 Wiley-Liss, Inc.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Stress and the brain: individual variability and the inverted-U.

                Bookmark

                Author and article information

                Contributors
                hsfutch@ufl.edu
                cara.croft@ufl.edu
                vtruong@ufl.edu
                EKrause@cop.ufl.edu
                tgolde@ufl.edu
                Journal
                Mol Neurodegener
                Mol Neurodegener
                Molecular Neurodegeneration
                BioMed Central (London )
                1750-1326
                21 June 2017
                21 June 2017
                2017
                : 12
                : 49
                Affiliations
                [1 ]ISNI 0000 0004 1936 8091, GRID grid.15276.37, Department of Neuroscience, , University of Florida, ; Gainesville, FL 32610 USA
                [2 ]ISNI 0000 0004 1936 8091, GRID grid.15276.37, Center for Translational Research in Neurodegenerative Disease, , University of Florida, ; Gainesville, FL 32610 USA
                [3 ]ISNI 0000 0004 1936 8091, GRID grid.15276.37, Department of Pharmacodynamics, College of Pharmacy, , University of Florida, ; Gainesville, USA
                [4 ]ISNI 0000 0004 1936 8091, GRID grid.15276.37, , McKnight Brain Institute, University of Florida, ; 1149 Newell Drive, PO Box 1000015, Gainesville, FL 32610 USA
                Article
                190
                10.1186/s13024-017-0190-z
                5479037
                28633663
                110e8ae1-445a-441c-b113-f8dd47d2f45b
                © The Author(s). 2017

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 18 April 2017
                : 8 June 2017
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/100000049, National Institute on Aging;
                Award ID: NIH U01AG046139
                Award ID: R01AG018454
                Award ID: P50AG047266
                Award Recipient :
                Categories
                Review
                Custom metadata
                © The Author(s) 2017

                Neurosciences
                alzheimer’s disease,corticotropin-releasing hormone,psychologic distress,chronic stress,neurodegeneration

                Comments

                Comment on this article